HIV Immune and Virological Responses Following the Administration of IL-2 Either Alone or Combined to ALVAC-HIV 1433 and HIV Lipopeptides in Patients Treated Early With HAART During Primary Infection

• Status: Terminated
• Trial end date: 2004-02-01
• Target enrollment: 0
• Participant gender: All

Summary

HIV-specific immune responses are preserved in patients treated early during primary infection.The trial evaluated whether the addition to HAART of IL-2 alone or combined with an immunization procedure might enhance HIV immune responses and improve viral control after HAART discontinuation

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
• Collaborator: Aventis Pharmaceuticals

Criteria

Inclusion Criteria:

• History of symptomatic HIV primary infection with p24 positive or incomplete Western Blot

• Treatment beginning before 4W after the first primary infection serology

• HAART with IP or NNRTI since one year, wtih no change since 3 months

• Viral load below 50 cp since 6 months

• PN over 1000/mm3;Hb over 10.5g/l;Platelets over 75000/mm3, creatinine below 1.5N; transaminases below 2.5N

Exclusion Criteria:

• Vaccination or chemotherapy or corticosteroid since 3 months

• Evolutive cancer

• pregnancy or breastfeeding